Pharmaceutical Investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Pharmaceutical Investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Nextech3D.ai Launches Blockchain Ticketing on the Ethereum Network With Coinbase and MetaMask Integration
Silver Hammer Enters into Option Agreement to Acquire 100% Interest in a Strategic and Prospective Silver Project in the Silver Valley of Idaho
